ProQR Therapeutics (PRQR) to Release Quarterly Earnings on Thursday

ProQR Therapeutics (NASDAQ:PRQR) is expected to be issuing its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect the company to announce earnings of ($0.15) per share and revenue of $5.1890 million for the quarter. Parties are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Thursday, May 21, 2026 at 12:30 PM ET.

ProQR Therapeutics (NASDAQ:PRQR) last released its quarterly earnings data on Thursday, March 12th. The biopharmaceutical company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.01). The business had revenue of $5.53 million for the quarter, compared to analysts’ expectations of $6.12 million. ProQR Therapeutics had a negative net margin of 255.83% and a negative return on equity of 65.89%. On average, analysts expect ProQR Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

ProQR Therapeutics Stock Up 1.9%

NASDAQ PRQR opened at $1.61 on Tuesday. The company has a market cap of $169.63 million, a PE ratio of -3.50 and a beta of 0.08. ProQR Therapeutics has a 52 week low of $1.33 and a 52 week high of $3.10. The firm’s 50-day simple moving average is $1.69 and its two-hundred day simple moving average is $1.89.

Wall Street Analysts Forecast Growth

PRQR has been the topic of several recent research reports. Oppenheimer initiated coverage on shares of ProQR Therapeutics in a report on Thursday, March 12th. They set an “outperform” rating and a $9.00 price objective on the stock. Citigroup reiterated a “market outperform” rating on shares of ProQR Therapeutics in a research report on Friday, March 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of ProQR Therapeutics in a research report on Tuesday, April 21st. Chardan Capital reiterated a “buy” rating and set a $4.00 price target on shares of ProQR Therapeutics in a research report on Thursday, April 9th. Finally, Wall Street Zen upgraded ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Saturday, March 14th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, ProQR Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $7.25.

Institutional Investors Weigh In On ProQR Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Diadema Partners LP increased its position in shares of ProQR Therapeutics by 6.2% during the fourth quarter. Diadema Partners LP now owns 167,532 shares of the biopharmaceutical company’s stock valued at $338,000 after buying an additional 9,838 shares during the period. Osaic Holdings Inc. raised its stake in ProQR Therapeutics by 59.6% in the second quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 4,500 shares in the last quarter. Persistent Asset Partners Ltd raised its stake in ProQR Therapeutics by 24.5% in the fourth quarter. Persistent Asset Partners Ltd now owns 45,154 shares of the biopharmaceutical company’s stock valued at $91,000 after purchasing an additional 8,874 shares in the last quarter. BNP Paribas Financial Markets raised its stake in ProQR Therapeutics by 28.4% in the second quarter. BNP Paribas Financial Markets now owns 121,494 shares of the biopharmaceutical company’s stock valued at $248,000 after purchasing an additional 26,893 shares in the last quarter. Finally, Walleye Capital LLC raised its stake in ProQR Therapeutics by 11.2% in the fourth quarter. Walleye Capital LLC now owns 591,785 shares of the biopharmaceutical company’s stock valued at $1,195,000 after purchasing an additional 59,808 shares in the last quarter. 32.65% of the stock is currently owned by institutional investors.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.